Evaluation after the final vaccine 1. One month after the final vacc ination subjects will undergo a leukapheresis. If the patient cannot undergo leukapheresis for any medical reason, they will undergo a 210 cc blood draw (same as at baseline and pre -vaccine #3). Additionally, patients will undergo a blood draw for clinica l monitoring of CBC (7 cc) and serum chemistries (7 cc). 2. Three months after the final vaccine subjects will undergo a MUGA and a 210 cc blood draw to obtain PBMC for T cell immunity studies. 3. Six and 12 months after the final vaccine, 210 cc of blood will be drawn for the evaluation of persistent antigen specific antibody and T cell immune responses. 4. After the final visit with us, patients may ask their regular physician to send us blood samples (about one cup) 3, 6 and 12 months after the final vaccine to test for the persistence of an immune response. If this cannot be arranged, they will need to come to the University of Washington for follow -up blood draws. 5. We may ask subjects to undergo leukapheresis at follow -up visits in lieu of a foll ow-up blood draw. This will done to recover more lymphocytes for immune function analysis. This will be determined on a case -by- case basis by the PI. Subjects will have the option to choose or refuse leukapheresis without affecting their continued partic ipation in the study. 6304p Protocol 118 04/06/2016 E.